Barclays
JNP

Barclays’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Barclays’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-497
Closed -$2K – 7151
2017
Q1 		$2K Buy
+497
New +$2.51K ﹤0.01% 6526
2016
Q2 		– Sell
-11,500
Closed -$69K – 6833
2016
Q1 		$69K Sell
11,500
-11,100
-49% -$81.7K ﹤0.01% 4602
2015
Q4 		$226K Buy
22,600
+18,600
+465% +$216K ﹤0.01% 3813
2015
Q3 		$44K Buy
+4,000
New +$44.2K ﹤0.01% 5084

Other funds holding JNP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AG
Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Barclays's JNP Position: Q2 2017 in Review

Barclays sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q2 2017, closing a stake of 497 shares — an estimated $2K sold.

Barclays first reported a position in JNP in Q3 2015 and held it in 4 quarters. The position peaked at $226K in Q4 2015. 33 funds tracked by Wall St. Rank hold JNP as of Q2 2017.

  • Barclays reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Barclays sold 497 Juniper Pharmaceuticals, Inc. Common Stock shares in Q2 2017, an estimated $2K.
  • Barclays first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2015 and held it in 4 quarters.
  • Barclays's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $226K in Q4 2015.
  • 33 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q2 2017.

Based on Barclays's 13F filing for Q2 2017, filed 14 Aug 2017.